<div><div></div><div><span><p><span>Telomir Pharmaceuticals, Inc. reported a first-quarter 2026 net loss of $(990,947) and no revenue as the company continues preclinical and early clinical preparations; diluted loss per share was $(0.03), improved from $(0.07) a year earlier, and cash is sufficient to fund operations into Q1 2027.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue was $0 for Q1 2026, unchanged from $0 in the year-ago quarter.</span></li><li><span>Net income was a loss of $(990,947) for Q1 2026, compared with a loss of $(2,179,828) in Q1 2025 (loss narrowed by 54.5%).</span></li><li><span>Diluted EPS was a loss of $(0.03) for Q1 2026, compared with $(0.07) in Q1 2025.</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Clinical milestone: The FDA cleared an IND for Telomir-1 (Telomir‑Zn) to begin a trial in advanced/metastatic triple-negative breast cancer (TNBC).</span></li><li><span>Pipeline consolidation: A merger with TELI unified global rights to Telomir‑1, simplifying development and potential commercialization.</span></li><li><span>Capital &amp; development funding: Bayshore Trust committed up to $5.0M, with $1.0M provided tied to IND acceptance and the start of a Phase 1/2 trial.</span></li><li><span>R&amp;D progress: Increased research and development spending and ongoing preclinical work to prepare for clinical trials across multiple indications.</span></li><li><span>Operational runway: Reported cash supports operations into Q1 2027, enabling near-term clinical and regulatory activities.</span></li></ul><p><span>Original SEC Filing: </span>Telomir Pharmaceuticals, Inc. [ TELO ] - 10-Q - May. 14, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

TELO

LABU

<p>Telomir Pharmaceuticals, Inc. reported a net loss of $(990,947) with no revenue for Q1 2026, an improvement from a $(2,179,828) loss in Q1 2025. Diluted EPS was $(0.03), better than $(0.07) a year earlier. The FDA cleared an IND for Telomir-1 to begin trials for advanced triple-negative breast cancer. A merger with TELI consolidated global rights to Telomir-1. Bayshore Trust committed up to $5.0M for funding, with $1.0M tied to IND acceptance. Cash is sufficient to fund operations into Q1 2027.</p>

TradingView

Telomir Pharmaceuticals

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary